MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231 Journal Article
| Authors: | Hayashi, R. J.; Hermiston, M. L.; Wood, B. L.; Teachey, D. T.; Devidas, M.; Chen, Z.; Annett, R. D.; Asselin, B. L.; August, K.; Cho, S.; Dunsmore, K. P.; Freedman, J. L.; Galardy, P. J.; Harker-Murray, P.; Horton, T. M.; Jaju, A.; Lam, A.; Messinger, Y. H.; Miles, R. R.; Okada, M.; Patel, S.; Schafer, E. S.; Schechter, T.; Shimano, K. A.; Singh, N.; Steele, A.; Sulis, M. L.; Vargas, S. L.; Winter, S. S.; Wood, C.; Zweidler-McKay, P. A.; Loh, M. L.; Hunger, S. P.; Raetz, E. A.; Bollard, C. M.; Allen, C. E. |
| Article Title: | MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231 |
| Abstract: | Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children's Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916. © 2024 American Society of Hematology |
| Keywords: | adolescent; adult; cancer chemotherapy; cancer survival; child; controlled study; event free survival; preschool child; child, preschool; disease-free survival; survival rate; young adult; major clinical study; overall survival; clinical trial; mortality; comparative study; disease free survival; cancer staging; flow cytometry; antineoplastic agent; bortezomib; randomized controlled trial; antineoplastic combined chemotherapy protocols; cohort analysis; clinical protocol; pathology; acute lymphoblastic leukemia; high risk patient; testis disease; age; proportional hazards model; infant; minimal residual disease; neoplasm, residual; multicenter study; phase 3 clinical trial; bone marrow cell; corticosteroid; gender; ethnicity; correlational study; race; leukemia remission; precursor t-cell lymphoblastic leukemia-lymphoma; central nervous system disease; intermediate risk patient; demographics; cancer prognosis; humans; prognosis; human; male; female; article; t cell acute lymphoblastic leukemia; b cell acute lymphoblastic leukemia; murphy stage |
| Journal Title: | Blood |
| Volume: | 143 |
| Issue: | 20 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-05-16 |
| Start Page: | 2053 |
| End Page: | 2058 |
| Language: | English |
| DOI: | 10.1182/blood.2023021184 |
| PUBMED: | 38457359 |
| PROVIDER: | scopus |
| PMCID: | PMC11143515 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
